title: IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma.
abstract: BACKGROUND
  IL-17A a member of IL-17 family of cytokines is an inflammatory cytokine produced by a subset of CD4+ T cells that links innate and adaptive immunity. IL-17A has been shown to be a key mediator of inflammation in autoimmune diseases, transplant rejection and cancers.
  
  
  OBJECTIVE
  To investigate the level of IL-17A in sera of southern Iranian patients with papillary serous cystadenocarcinoma of ovary and compare it with age-matched women of the same region.
  
  
  METHODS
  In this study we investigated IL-17A and CA125 levels in sera of 26 patients with ovarian serous cystadenocarcinoma and 62 healthy age matched women by commercial ELISA assays.
  
  
  RESULTS
  Fifteen (58%) and 16 (61.5%) out of 26 patients showed elevated IL-17A (1.25 ± 2.25 pg/ml) and CA125 (218 ± 224.69 IU/ml) in their sera, respectively. No healthy individual had detectable IL-17A or elevated CA125 in their sera (8.85 ± 2.86 IU/ml). The mean IL-17A levels in poorly differentiated tumors (3.33 ± 2.36 pg/ml) was significantly higher than that of well differentiated (0.14 ± 0.38 pg/ml) and moderately differentiated (undetectable) tumors. There was also a positive correlation between IL-17A and CA125 in sera of patients and controls when grouped together (r=0.37, p=0.005).
  
  
  CONCLUSIONS
  Elevation of IL-17A in a high percentage of ovarian serous cystadenocarcinoma and lack of this cytokine in healthy individuals makes it a specific candidate in diagnosis, follow up or immunotherapy.
authors.affiliation: Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Mahyar
authors.initials: M
authors.lastname: Malekzadeh
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Alamtaj Samsami
authors.initials: AS
authors.lastname: Dehaghani
authors.affiliation: Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Abbas
authors.initials: A
authors.lastname: Ghaderi
authors.affiliation: Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: Mehrnoosh
authors.initials: M
authors.lastname: Doroudchi
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D002454:Cell Differentiation / Q000502:physiology; D015331:Cohort Studies; D018284:Cystadenocarcinoma, Serous / Q000097:blood* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000097:blood*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D020381:Interleukin-17
keywords: CA125; IL-17A; Serous cystadenocarcinoma; ovarian tumor